A citation-based method for searching scientific literature

Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
Times Cited: 57



Michael A Weber, Traci A Mansfield, Valerie A Cain, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Lancet Diabetes Endocrinol 2016
Times Cited: 128




List of shared articles



Times cited

SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
Konstantinos Imprialos, Charles Faselis, Chrysoula Boutari, Konstantinos Stavropoulos, Vasilios Athyros, Asterios Karagiannis, Michael Doumas. Curr Pharm Des 2017
10

Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

EMPA-REG OUTCOME: The Cardiologist's Point of View.
Son V Pham, Robert Chilton. Am J Med 2017
7


The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
Eirini Lioudaki, Emmanouil S Androulakis, Martin Whyte, Konstantinos G Stylianou, Eugenios K Daphnis, Emmanouil S Ganotakis. Cardiovasc Drugs Ther 2017
6

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.
Karin Rådholm, Jason Hy Wu, Muh Geot Wong, Celine Foote, Gregory Fulcher, Kenneth W Mahaffey, Vlado Perkovic, Bruce Neal. Diabetes Res Clin Pract 2018
41


Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
3


Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Surender Kumar, Pradeep G Talwalkar, Sambit Das, Soumik Goswami. Indian J Endocrinol Metab 2019
1




Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.
Elias A Sanidas, Dimitrios P Papadopoulos, Erifili Hatziagelaki, Charalampos Grassos, Maria Velliou, John Barbetseas. Am J Hypertens 2020
6

Blood pressure control in type 2 diabetic patients.
Alon Grossman, Ehud Grossman. Cardiovasc Diabetol 2017
27


Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Aris Liakos, Vaia Lambadiari, Alexandra Bargiota, Konstantinos Kitsios, Iakovos Avramidis, Kalliopi Kotsa, Spyridon Gerou, Panagiota Boura, Nikolaos Tentolouris, George Dimitriadis,[...]. Diabetes Obes Metab 2019
13

EMPA-REG OUTCOME: The Cardiologist's Point of View.
Son V Pham, Robert J Chilton. Am J Cardiol 2017
16

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
William L Baker, Leo F Buckley, Michael S Kelly, John D Bucheit, Eric D Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L Dixon. J Am Heart Assoc 2017
73

Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
Charalampos I Liakos, Dimitrios P Papadopoulos, Elias A Sanidas, Maria I Markou, Erifili E Hatziagelaki, Charalampos A Grassos, Maria L Velliou, John D Barbetseas. Am J Cardiovasc Drugs 2021
1

Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
Keith C Ferdinand, Joseph L Izzo, Jisoo Lee, Leslie Meng, Jyothis George, Afshin Salsali, Leo Seman. Circulation 2019
30


The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros. Expert Rev Clin Pharmacol 2017
7

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Theodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S Elisaf. Postgrad Med 2019
24

Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019
0


Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
0

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
Tricia Santos Cavaiola, Jeremy Pettus. Diabetes Metab Syndr Obes 2018
12

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
60


The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
13

The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis, Pantelis Sarafidis. Curr Med Chem 2020
11